| Breast cancer early detection: A phased approach to implementation O Ginsburg, CH Yip, A Brooks, A Cabanes, M Caleffi, JA Dunstan Yataco, ... Cancer 126, 2379-2393, 2020 | 321 | 2020 |
| Assessment of the clinical benefit of cancer drugs receiving accelerated approval B Gyawali, SP Hey, AS Kesselheim JAMA internal medicine 179 (7), 906-913, 2019 | 210 | 2019 |
| Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis B Dhakal, A Szabo, S Chhabra, M Hamadani, A D’Souza, SZ Usmani, ... JAMA oncology 4 (3), 343-350, 2018 | 153 | 2018 |
| Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional … H Naci, C Davis, J Savović, JPT Higgins, JAC Sterne, B Gyawali, ... bmj 366, 2019 | 109 | 2019 |
| Financial toxicity of cancer treatment: moving the discussion from acknowledgement of the problem to identifying solutions A Desai, B Gyawali EClinicalMedicine 20, 2020 | 99 | 2020 |
| Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer N Hayashi, Y Ando, B Gyawali, T Shimokata, O Maeda, M Fukaya, H Goto, ... Oncology reports 35 (3), 1727-1731, 2016 | 89 | 2016 |
| Evolution of the randomized clinical trial in the era of precision oncology JC Del Paggio, JS Berry, WM Hopman, EA Eisenhauer, V Prasad, ... JAMA oncology 7 (5), 728-734, 2021 | 87 | 2021 |
| ReDO_DB: the repurposing drugs in oncology database P Pantziarka, C Verbaanderd, V Sukhatme, IR Capistrano, S Crispino, ... ecancermedicalscience 12, 2018 | 87 | 2018 |
| Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence. A Passaro, G Spitaleri, B Gyawali, F de Marinis Journal of Clinical Oncology: Official Journal of the American Society of …, 2019 | 81 | 2019 |
| Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs B Gyawali, SP Hey, AS Kesselheim EClinicalMedicine 21, 2020 | 79 | 2020 |
| Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines TJ Hwang, JM Franklin, CT Chen, JC Lauffenburger, B Gyawali, ... J Clin Oncol 36 (18), 1805-1812, 2018 | 79 | 2018 |
| Association between progression‐free survival and patients’ quality of life in cancer clinical trials TJ Hwang, B Gyawali International journal of cancer 144 (7), 1746-1751, 2019 | 77 | 2019 |
| An analysis of contemporary oncology randomized clinical trials from low/middle-income vs high-income countries JC Wells, S Sharma, JC Del Paggio, WM Hopman, B Gyawali, D Mukherji, ... JAMA oncology 7 (3), 379-385, 2021 | 76 | 2021 |
| Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey A Fundytus, M Sengar, D Lombe, W Hopman, M Jalink, B Gyawali, ... The Lancet Oncology 22 (10), 1367-1377, 2021 | 57 | 2021 |
| An arm and a leg: the rising cost of cancer drugs and impact on access NB Leighl, S Nirmalakumar, DA Ezeife, B Gyawali American Society of Clinical Oncology Educational Book 41, e1-e12, 2021 | 57 | 2021 |
| Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer B Gyawali, A Ota, Y Ando The New England Journal of Medicine 374 (5), 493, 2016 | 57* | 2016 |
| A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and … B Gyawali, SP Hey, AS Kesselheim JAMA Network Open 1 (2), e180416-e180416, 2018 | 54 | 2018 |
| Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer K Honda, B Gyawali, M Ando, R Kumanishi, K Kato, K Sugiyama, S Mitani, ... Journal of global oncology 5, 1-8, 2019 | 52 | 2019 |
| Economics of cancer medicines: for whose benefit? B Gyawali, R Sullivan The new bioethics 23 (1), 95-104, 2017 | 52 | 2017 |
| Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study B Gyawali, BN Rome, AS Kesselheim bmj 374, 2021 | 47 | 2021 |
Christopher M. Booth MD FRCPCProfessor of Oncology, Queen's University在 kgh.kari.net 的电子邮件经过验证
